31062296|t|CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice.
31062296|a|Efavirenz, the FDA-approved anti-retroviral medication, is evaluated in the clinical trial in patients with mild cognitive impairment or early dementia due to Alzheimer's disease. Efavirenz is assessed for activation of cytochrome P450 46A1 (CYP46A1), a CNS-specific enzyme that converts cholesterol to 24-hydroxycholesterol. Cholesterol 24-hydroxylation is the major pathway for brain cholesterol removal, and a mechanism that controls brain cholesterol turnover. The present study tested efavirenz on 5XFAD mice (an Alzheimer's model) at a very low daily dose of 0.1 mg/kg body weight. Efavirenz treatment started from three months of age, after amyloid plague appearance, and continued for 6 months. This treatment led to CYP46A1 activation in the brain, enhancement of brain cholesterol turnover, behavioral improvements, reduction in microglia activation but increased astrocyte reactivity. The levels of the soluble and insoluble amyloid 40 and 42 peptides were unchanged while the number and area of the dense core amyloid plaques were slightly decreased. The measurements of the brain levels of several pre- and post-synaptic proteins (Munc13-1, PSD-95, gephyrin, synaptophysin, synapsin-1, and calbindin-D28k) suggested efavirenz effect at the synaptic level. Efavirenz treatment in the present work seems to represent a model of behavioral and other improvements independent of the levels of the amyloid peptides and provides insight into potential outcomes of the future clinical trial.
31062296	0	7	CYP46A1	Gene	13116
31062296	22	31	Efavirenz	Chemical	MESH:C098320
31062296	131	136	5XFAD	Disease	
31062296	137	141	Mice	Species	10090
31062296	143	152	Efavirenz	Chemical	MESH:C098320
31062296	237	245	patients	Species	9606
31062296	256	276	cognitive impairment	Disease	MESH:D003072
31062296	286	294	dementia	Disease	MESH:D003704
31062296	302	321	Alzheimer's disease	Disease	MESH:D000544
31062296	323	332	Efavirenz	Chemical	MESH:C098320
31062296	363	383	cytochrome P450 46A1	Gene	13116
31062296	385	392	CYP46A1	Gene	13116
31062296	431	442	cholesterol	Chemical	MESH:D002784
31062296	446	467	24-hydroxycholesterol	Chemical	MESH:C044563
31062296	469	480	Cholesterol	Chemical	MESH:D002784
31062296	529	540	cholesterol	Chemical	MESH:D002784
31062296	586	597	cholesterol	Chemical	MESH:D002784
31062296	633	642	efavirenz	Chemical	MESH:C098320
31062296	646	651	5XFAD	Disease	
31062296	652	656	mice	Species	10090
31062296	661	672	Alzheimer's	Disease	MESH:D000544
31062296	731	740	Efavirenz	Chemical	MESH:C098320
31062296	791	805	amyloid plague	Disease	MESH:D010930
31062296	868	875	CYP46A1	Gene	13116
31062296	922	933	cholesterol	Chemical	MESH:D002784
31062296	1165	1172	amyloid	Disease	MESH:C000718787
31062296	1287	1295	Munc13-1	Gene	382018
31062296	1297	1303	PSD-95	Gene	13385
31062296	1305	1313	gephyrin	Gene	268566
31062296	1315	1328	synaptophysin	Gene	20977
31062296	1330	1340	synapsin-1	Gene	20964
31062296	1346	1360	calbindin-D28k	Gene	12307
31062296	1372	1381	efavirenz	Chemical	MESH:C098320
31062296	1412	1421	Efavirenz	Chemical	MESH:C098320
31062296	Negative_Correlation	MESH:C098320	MESH:C000718787
31062296	Association	MESH:C044563	13116
31062296	Negative_Correlation	MESH:C098320	MESH:D003072
31062296	Positive_Correlation	MESH:C044563	MESH:C098320
31062296	Negative_Correlation	MESH:C098320	MESH:D003704
31062296	Negative_Correlation	MESH:C098320	MESH:D000544
31062296	Positive_Correlation	MESH:C098320	13116
31062296	Association	MESH:C098320	382018
31062296	Association	MESH:C098320	13385
31062296	Negative_Correlation	MESH:C098320	MESH:D010930
31062296	Association	MESH:C098320	20977
31062296	Association	MESH:C044563	MESH:D002784
31062296	Association	MESH:C098320	268566
31062296	Association	MESH:D002784	13116
31062296	Association	MESH:C098320	MESH:D002784
31062296	Association	MESH:C098320	12307
31062296	Association	MESH:C098320	20964

